bimekizumab
IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis
Phil Taylor
bimekizumab, Bimzelx, Cosentyx, dermatology, EU, Novartis, psoriasis, regulatory approval, UCB
0 Comment
X
IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis
https://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/
UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme
Phil Taylor
bimekizumab, dermatology, HEOR, NICE, psoriasis, UCB
0 Comment
X
UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme
https://pharmaphorum.com/news/ucbs-bimekizumab-pre-approved-using-nice-fast-track-scheme/
News/ News/ R&D/ Top stories
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial
Phil Taylor
bimekizumab, comparator clinical trials, Cosentyx, dermatology, Novartis, psoriasis, UCB
0 Comment
X
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial
https://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/
X
UCB posts more supportive data from Humira rival bimekizumab
https://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/
UCB’s bimekizumab tops J&J’s Stelara in psoriasis study
Phil Taylor
bimekizumab, IL-17A, IL-17F, psoriasis, UCB
0 Comment
X
UCB’s bimekizumab tops J&J’s Stelara in psoriasis study
https://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/